GH Research reports second quarter 2026 financial results
Net loss was $15.1 million, or $0.23 per share, with cash, cash equivalents and marketable securities of $362.7 million as of June 30, 2026.
Latest GH Research News & Updates
See the latest news and media coverage for GH Research. We track all announcements, press releases, and industry mentions in real time, all in one place.
Clinical-stage pharmaceutical company developing psychiatric and neurological treatments
ghres.com- Founded year
- 2018
- Company type
- Public company
- Number of employees
- 50–71
- Industry
- Pharmaceuticals
Last updated
Latest news about GH Research
In short: GH Research reported positive postpartum depression results as the FDA lifted GH001’s clinical hold
Company announcements
GH Research reports first quarter 2026 financial results
Net loss was $19.0 million, or $0.31 per share, and cash totaled $267.3 million; it completed enrolment in two Phase 1 GH001 studies
GH Research prices $117.5 million underwritten offering
It offers 6,527,779 ordinary shares at $18.00 per share, with closing expected on April 30, 2026, subject to customary conditions.
GH Research reports $48.3 million net loss for 2025
Cash and marketable securities total $280.7 million; its Phase 2b trial of GH001 met the primary endpoint with a -15.5 MADRS reduction at Day 8.
Media coverage
GH Research to Present TRD and Bipolar Trial Data at ECNP 2026 - TipRanks.com
GH Research ( ($GHRS) ) has issued an announcement. GH Research PLC announced that data from its GH001-TRD-201 and GH001-BD-202 clinical trials will be presented...
Assessing GH Research (GHRS) Valuation After FDA Lifts Clinical Hold On GH001 Trials
GH Research (NasdaqGM:GHRS) is back in focus after the FDA lifted the clinical hold on its IND for GH001, clearing the way for U.S. enrollment...
A small company can now advance its psychedelic into Phase 3. Here’s why that matters to other psychedelic biotechs.
A small biopharma company said its experimental depression drug is moving into Phase 3 trials, sending its shares soaring about 35% in premarket trading on...
GH Research PLC Provides Update on GH001 IND Response and Phase 2b Clinical Trial Results in Treatment-Resistant Depression
GH Research PLC has provided updates on its GH001 treatment for depression, reporting completion of the Open-Label Extension analysis that shows a 73% remission rate...
Never miss news about GH Research
Track GH Research and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
GH Research competitors & trending companies
Browse news for competitors to GH Research and other trending companies.
LB
Gabather
Definium Therapeutics
AtaiBeckley
Helus
Compass
RG
Curis
MPLX
Mosaic
Fortitude Re
Brit
Convex
Sompo
Somers Group
Pelagos
Vantage
Premia
Mereo
Longtail Re
Assured Guaranty
BMA
NAIC
IAIS
Ascot
GFIA
SiriusPoint
Lancashire
AXIS
White Mountains
PartnerRe
Antares
Lockton Finland
RenaissanceRe
MS Re
Aeolus